MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.
Record first quarter revenue reflects a strong start to 2021
Revenue for the first quarter of 2021 was $29.0 million, representing an 86% increase compared with $15.6 million for the first quarter of 2020. The Company placed 41 Sequel II/IIe systems during the first quarter of 2021 compared to 11 Sequel II systems placed in the first quarter of 2020 and 35 Sequel II/IIe systems placed during the fourth quarter of 2020, bringing the total installed base of Sequel II/IIe systems to 244 as of March 31, 2021, compared with 125 as of March 31, 2020 and 203 as of December 31, 2020. Instrument revenue for the first quarter of 2021 was $14.9 million, compared with $4.0 million for the first quarter of 2020. Consumables revenue for the first quarter of 2021 was $10.4 million compared with $8.3 million for the first quarter of 2020. Service and other revenue for the first quarter of 2021 was $3.7 million compared with $3.3 million for the first quarter of 2020.
Gross profit for the first quarter of 2021 was $13.0 million, representing a 73% increase compared with $7.5 million for the first quarter of 2020. Gross margin for the first quarter of 2021 was 45%, compared to 48% for the first quarter of 2020.
Operating expenses totaled $46.7 million for the first quarter of 2021, compared to $40.2 million for the first quarter of 2020. Operating expenses for the first quarter of 2021 and first quarter of 2020 included non-cash stock-based compensation of $9.2 million and $3.5 million, respectively.
Net loss for the first quarter of 2021 was $87.4 million, compared to a net income of $1.3 million for the first quarter of 2020. The net loss for the first quarter of 2021 was largely driven by the repayment of $52 million of Continuation Advances to Illumina in the first quarter of 2021 as a result of the investment from SoftBank. First quarter 2020 included $34 million in other income from Continuation Advances from Illumina.
Basic and diluted net loss per share for the first quarter of 2021 was $0.45 per share compared to basic and diluted net income of $0.01 per share for the first quarter of 2020.
In February 2021, SB Northstar LP, a subsidiary of SoftBank Group Corp., made an investment of $900 million in convertible senior notes to support the Company’s future growth initiatives. Cash, cash equivalents and investments, excluding short and long-term restricted cash, at March 31, 2021 totaled $1,160.3 million, compared to $318.8 million at December 31, 2020.
Updates since our last earnings release
- Released a new HiFi workflow and an updated software version that increases the number of reads at or above 99.9% accuracy, scales workflows to sequence hundreds to thousands of whole human genomes per year, and opens up more sample types to HiFi sequencing.
- Shipped four additional Sequel IIe Systems to Children’s Mercy Kansas City, significantly increasing their whole genome sequencing capabilities to identify potential disease-causing variants for children living with undiagnosed diseases.
- Deployed Sequel IIe systems at LabCorp to scale their capabilities to sequence SARS-CoV-2.
- Announced Hannah Valantine, M.D., as a director nominee for election to the Board of Directors at this year’s annual meeting of stockholders; Dr. Valantine has decades of experience as Professor of Medicine at the Stanford University Medical Center and as the NIH Chief Officer for Scientific Workforce Diversity.
“PacBio is off to a great start in 2021 as we achieved record revenue in the first quarter that exceeded our expectations,” said Christian Henry, President and Chief Executive Officer. “We installed a record number of Sequel II Systems and recorded our fourth straight quarter of sequential growth. In the first quarter, we made excellent progress on our strategic initiatives, and we remain in the early stages of the impact that PacBio sequencing can have on human health.”
Impact of COVID-19 Pandemic
Financial results for the first three months of 2020 were negatively impacted as multiple customers postponed system deliveries, and the financial results for much of 2020 were further impacted as several customers shut down or limited operations for various periods to help curb the spread of the COVID-19 pandemic. Instrument utilization largely returned to normal by the fourth quarter of 2020, and we subsequently have not seen significant issues with deliveries or operations at customer sites. This resulted in higher product revenues of $25.3 million for the first quarter of 2021 compared to $12.3 million for the same period of 2020. Uncertainties associated with the pandemic, including recent resurgences in infection rates, may cause further impacts to our operations and financial results.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its first quarter ended March 31, 2021 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using Conference ID # 9858326. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at https://investor.pacificbiosciences.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, our preliminary financial results for the first quarter ended March 31, 2021, including our revenue, instrument revenue, consumable revenue and service and other revenue and our installed instruments during the quarter, sequential growth and factors such as limits or interruptions in chip supplies that could impact our growth, customer interest in SMRT Sequencing with HiFi reads, sales momentum, the accuracy, throughput and benefits of HiFi reads and the capabilities of SMRT sequencing, progress on Company initiatives and the impact the Company can have on human health, the impact of COVID-19 on our business, the nomination of Dr. Valantine to our Board, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
The condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in the Pacific Biosciences’ Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
| Three Months Ended | |||||||||||
| March 31, 2021 | December 31, 2020 | March 31, 2020 | |||||||||
| Revenue: | |||||||||||
| Product revenue | $ | 25,303 | $ | 23,626 | $ | 12,293 | |||||
| Service and other revenue | 3,694 | 3,510 | 3,305 | ||||||||
| Total revenue | 28,997 | 27,136 | 15,598 | ||||||||
| Cost of Revenue: | |||||||||||
| Cost of product revenue | 12,697 | 12,550 | 5,421 | ||||||||
| Cost of service and other revenue | 3,323 | 3,185 | 2,689 | ||||||||
| Total cost of revenue | 16,020 | 15,735 | 8,110 | ||||||||
| Gross profit | 12,977 | 11,401 | 7,488 | ||||||||
| Operating Expense: | |||||||||||
| Research and development | 20,548 | 17,425 | 15,250 | ||||||||
| Sales, general and administrative | 26,139 | 17,953 | 24,947 | ||||||||
| Total operating expense | 46,687 | 35,378 | 40,197 | ||||||||
| Operating loss | (33,710 | ) | (23,977 | ) | (32,709 | ) | |||||
| Gain from Reverse Termination Fee from Illumina | — | 98,000 | — | ||||||||
| Gain (loss) from Continuation Advances from Illumina | (52,000 | ) | — | 34,000 | |||||||
| Interest expense | (1,789 | ) | — | (267 | ) | ||||||
| Other income, net | 64 | 912 | 238 | ||||||||
| Net income (loss) | $ | (87,435 | ) | $ | 74,935 | $ | 1,262 | ||||
| Net income (loss) per share | |||||||||||
| Basic | $ | (0.45 | ) | $ | 0.40 | $ | 0.01 | ||||
| Diluted | $ | (0.45 | ) | $ | 0.37 | $ | 0.01 | ||||
| Weighted average shares outstanding used in calculating net income (loss) per share | |||||||||||
| Basic | 194,790 | 186,013 | 153,453 | ||||||||
| Diluted | 194,790 | 203,822 | 155,855 | ||||||||
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
| March 31, | December 31, | ||||
| 2021 | 2020 | ||||
| Assets | |||||
| Cash and investments | $ | 1,160,319 | $ | 318,814 | |
| Accounts receivable | 12,906 | 16,837 | |||
| Inventory | 16,268 | 14,230 | |||
| Prepaid and other current assets | 5,623 | 4,870 | |||
| Property and equipment, net | 24,207 | 24,899 | |||
| Operating lease right-of-use assets, net | 29,162 | 29,951 | |||
| Restricted cash | 4,336 | 4,336 | |||
| Other long-term assets | 67 | 43 | |||
| Total Assets | $ | 1,252,888 | $ | 413,980 | |
| Liabilities and Stockholders' Equity | |||||
| Accounts payable | $ | 3,471 | $ | 3,579 | |
| Accrued expenses | 14,672 | 17,350 | |||
| Deferred revenue | 15,294 | 10,290 | |||
| Operating lease liabilities | 40,933 | 41,999 | |||
| Convertible senior notes, net | 895,674 | — | |||
| Other liabilities | 2,291 | 5,271 | |||
| Stockholders' equity | 280,553 | 335,491 | |||
| Total Liabilities and Stockholders' Equity | $ | 1,252,888 | $ | 413,980 | |